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Nomenclature and Abbreviations 
AUC Area under the ROC curve 
DVT Deep vein thrombosis    
hs-CRP High-sensitivity C-reactive protein    
hs-cTnT High-sensitivity cardiac Troponin T     
IDI Integrated discrimination improvement   
NRI Net reclassification improvement  
NT-proBNP NT-pro B-type natriuretic peptide    
PE Pulmonary embolism    
PESI Pulmonary embolism severity index    
ROC Receiver operating characteristic  
SWITCO65+ SWIss venous Thromboembolism COhort of patients aged ≥65 years   
VTE Venous thromboembolism 
 
Essentials 
 Do hs-cTnT, NT-proBNP, hs-CRP improve risk prediction of patients with pulmonary 
embolism (PE) beyond the PESI risk score? 
 In elderly patients with PE we studied the PESI risk score and these 3 markers for 6-
month mortality. 
 Adding these markers to the PESI risk score had no clinically relevant impact on risk 
stratification. 
 In elderly patients with PE, 6-month mortality can be predicted by the PESI risk score 
alone.  
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Abstract 
Background: Combining high-sensitivity cardiac Troponin T (hs-cTnT), NT-pro-B-type 
natriuretic peptide (NT-proBNP) and high-sensitivity C-reactive protein (hs-CRP) may improve 
risk stratification of patients with pulmonary embolism (PE) beyond the PESI risk score. 
Methods: In the prospective multicenter SWITCO65+ study, we analyzed 214 patients ≥65 
years with a new submassive PE. Biomarkers and clinical information for the PESI risk score 
were ascertained within 1 day after diagnosis. Associations of hs-TnT, NT-proBNP, hs-CRP 
and the PESI risk score with the primary endpoint defined as 6-month mortality were assessed. 
The discriminative power of the PESI risk score and its combination with hs-cTnT, NT-proBNP 
and hs-CRP for 6-month mortality was compared using integrated discrimination improvement 
(IDI) index and net reclassification improvement (NRI). 
Results: Compared with the lowest quartile, patients in the highest quartile had a higher risk of 
death during the first 6 months for hs-cTnT (adjusted HR 10.22; 95% CI 1.79-58.34; p=0.009), 
and a trend for NT-proBNP (adjusted HR 4.3; 95% CI 0.9-20.41; p=0.067) unlike hs-CRP 
(adjusted HR 1.97; 95% CI 0.48-8.05; p=0.344). The PESI risk score (c-statistic 0.77 (95% CI 
0.69-0.84) had the highest prognostic accuracy for 6-month mortality, outperforming hs-cTnT, 
NT-proBNP and hs-CRP (c-statistics of 0.72, 0.72, and 0.54), respectively. Combining all three 
biomarkers had no clinically relevant impact on risk stratification when added to the PESI risk 
score (IDI = 0.067; 95% CI 0.012-0.123; p=0.018; NRI = 0.101 95% CI -0.099-0.302; p=0.321).  
Conclusions: In elderly patients with PE, 6-month mortality can adequately be predicted by 
the PESI risk score alone. 
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Introduction 
Venous thromboembolism (VTE) is a major contributor to global morbidity and mortality [1]. 
The incidence of VTE increases with higher age and hospital-associated VTE is an important 
cause of disability-adjusted-life-years lost, especially in low- and middle-income countries [1, 
2]. 
Within the spectrum of VTE, pulmonary embolism (PE) constitutes a potentially life-
threatening condition: The short-term mortality of PE ranges from less than 2% in low-risk 
patients to more than 95% in patients with cardiac arrest following PE [3-5]. In patients with PE 
without hemodynamic instability, the individual risk of early mortality can be estimated by 
determination of the Pulmonary Embolism Severity Index (PESI) risk score [6, 7] as 
recommended by the current European Society of Cardiology (ESC) guidelines to identify very 
low-risk patients eligible for outpatient treatment [8]. While the PESI risk score is exclusively 
based on clinical parameters, recent data have shown that the addition of cardiovascular 
biomarkers, such as high-sensitivity cardiac troponin T (hs-cTnT) and the precursor of brain 
natriuretic peptide, N-terminal pro-brain natriuretic peptide (NT-proBNP) may further improve 
risk stratification for PE-related complications or PE-related mortality in elderly 
hemodynamically stable patients with PE [8-10]. Of note, these previous studies did not 
specifically relate the added value of these markers to the PESI risk score for all-cause 
mortality and C-reactive protein was not included. Indeed, at 3 months, all-cause mortality is 
more frequent than PE-related mortality (6.5% vs. 2.3%) [11]. 
Systemic inflammation is a central component of cardiovascular risk with the circulating 
C-reactive protein (CRP) representing the most extensively studied pro-inflammatory 
biomarker. In particular, high-sensitivity CRP (hs-CRP) was found to be accurate in 
cardiovascular risk prediction in primary [12] and secondary prevention after acute coronary 
syndromes [13] where it guided an anti-interleukin 1 antibody therapy to reduce major 
adverse cardiovascular events [14]. 
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Unlike in coronary and other atherosclerotic diseases [15-18], the role of hs-CRP in 
VTE remains less clear: Controversy remains on its role in risk stratification before the 
occurrence of VTE [19-21], whereas levels of hs-CRP were consistently found to be elevated 
after a VTE episode [22, 23]. A small study related hs-CRP levels to short-term in-hospital 
outcome: The authors found increased hs-CRP levels in patients with decreased reperfusion 
after fibrinolytic therapy and in patients with massive PE [24]. However, the role of hs-CRP in 
risk stratification after pulmonary embolism (PE) without hemodynamic compromise in elderly 
patients remains unclear. 
Thus, we compared the prognostic accuracy of hs-CRP with cardiac biomarkers (hs-
cTnT, NT-proBNP) and investigated whether these biomarkers provide incremental prognostic 
value to predict all-cause mortality beyond the PESI risk score in elderly patients with acute 
PE without hemodynamic instability. 
 
Materials and Methods 
Patient population 
Consecutive patients with a diagnosis of VTE aged ≥65 years were enrolled into the SWIss 
venous Thromboembolism COhort (SWITCO65+) study between September 2009 and March 
2012 (ClinicalTrials.gov; NCT00973596). 
The SWITCO65+ study is a prospective multicenter cohort study on long-term medical 
outcomes in patients aged ≥65 years with acute, symptomatic deep vein thrombosis (DVT) or 
PE from five university hospitals and four high-volume non-university hospitals in Switzerland 
[25]. Only patients with an objectively diagnosed acute symptomatic, haemodynamically stable 
PE, in whom blood samples were drawn within 24 hours after the diagnosis of PE and clinical 
information to calculate the PESI risk score was ascertained within the first day after diagnosis 
were analysed in the current study. Symptomatic PE was defined by a positive test using spiral 
computed tomography or pulmonary angiography or a high probability ventilation-perfusion 
scan in patients with acute chest pain, new or worsening dyspnoea, haemoptysis, or syncope 
[25]. 
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Exclusion criteria comprised catheter-related thrombosis, thrombosis at different site 
than lower limb, insufficient ability to understand German- or French, inability to provide 
informed consent, conditions incompatible with follow-up (e.g., terminal illness), and previous 
enrolment in the same study. In the current analysis patients had to be treated with 
anticoagulation and had to be free of severe infection or sepsis in the preceding 3 months. The 
study was approved by the local ethics committees. Informed consent was obtained from all 
study participants. A detailed description of the study methods has previously been published 
[25]. 
 
Clinical and laboratory characteristics 
Baseline demographic and clinical data (age, gender, body mass index (BMI), systolic blood 
pressure, heart rate, respiratory rate, arterial oxygen saturation, smoking status) as well as 
data on medication (lipid lowering medication, estrogen therapy, antiplatelet medication; initial 
vitamin K antagonists (VKA) and initial parenteral anticoagulation) were collected by trained 
study nurses and recorded on standardised data collection forms. Clinically relevant 
comorbidities (diabetes mellitus, arterial hypertension, coronary artery disease, chronic/acute 
heart failure, chronic lung disease, chronic liver disease, chronic renal disease, active cancer, 
severe infection or sepsis, and history of major bleeding) were documented. The history of 
prior VTE was also routinely obtained in all patients. The presence of an underlying cause of 
VTE was determined to differentiate between provoked vs. unprovoked VTE. 
The PESI risk score was determined in all included patients based on available clinical 
data ascertained at study inclusion within 24 hours. Routine blood work was performed locally, 
comprising leukocyte, platelet, haemoglobin, and D-dimer concentrations, respectively. All 
data were entered in an electronic database. 
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Biomarker measurements 
Venous blood was drawn at the time of enrolment and centrifuged at 2700g for 10 min at room 
temperature to obtain serum, frozen, and stored in aliquots at -80°C at University Hospital 
Lausanne (central biobank) until serial measurement (no prior freeze-thaw cycles). In the 
current study, only patients with blood drawn within 1 day of diagnosis of PE were analysed. 
NT-proBNP and hs-cTnT were measured in serum aliquots at University Hospital Geneva 
using an electrochemiluminescence immunoassay (cobas e602 reader; Roche Diagnostics, 
Mannheim, Germany) and hs-CRP was measured at University Hospital Zurich in serum 
aliquots using a latex-enhanced immunoturbidimetric assay on a cobas c501 autoanalyser 
(Roche Diagnostics, Mannheim, Germany) with assay characteristics as reported by the 
manufacturer. 
 
Clinical endpoints 
A clinical follow-up visit was performed at 3 months and a telephone follow-up at 6 months. 
The primary outcome for this study was all-cause mortality within 6 months after diagnosis of 
PE enabling assessment of the prognostic accuracy of biomarkers against the PESI risk score 
as a reference model [6, 7]. 
Outcomes were assessed using patient or proxy interviews, interview of the patient’s 
primary care physician, and/or hospital chart review. A committee of three blinded, 
independent clinical experts adjudicated all outcomes and classified the cause of all deaths as 
definitely due to PE, possibly due to PE, due to major bleeding, or due to another cause. Final 
classifications were made on the basis of the full consensus of this committee [25]. 
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Statistical analyses 
Hs-CRP, hs-cTnT, and NT-proBNP levels were categorised into low, medium, and high level 
groups using the 25th and 75th percentile as pre-specified cut-offs.  
We examined associations between log-transformed and categorized biomarker values and 
the time to all-cause death up to six months using ordinary Cox regression with robust 
standard errors. We used competing risk regression according to Fine and Gray [26] to 
explore the association between biomarker values and the time to PE- and cancer-related 
death and the time of a first VTE recurrence and a first major bleeding up to six months, 
accounting for non-PE-, non-cancer-, and non-bleeding-related death as a competing event, 
respectively. The strength of the association between biomarker levels and the event is 
reflected by the sub-hazard ratio (SHR), which is the ratio of hazards associated with the 
cumulative incidence function in the presence of a competing risk. Models were adjusted for 
clinical variables previously shown to be associated with the respective outcome and periods 
of anticoagulation as a time-varying covariate. All-cause mortality was adjusted for age, 
gender, active cancer, provoked VTE, heart failure, chronic lung disease, and periods of 
anticoagulation as a time-varying covariate. We assumed missing values in adjustment 
variables to be normal/absent. 
The discriminative power of the PESI risk score, hs-CRP, hs-cTnT, NT-proBNP, and 
combinations thereof, for 6-month mortality was assessed by Harrell’s C concordance statistic 
for time-to-event outcomes and the area under the ROC curve (AUC) for binary outcomes. 
The added predictive ability of single biomarkers and combinations of biomarkers when added 
to the PESI risk score were assessed by the integrated discrimination improvement (IDI) index 
and the net reclassification improvement (NRI). The IDI is based on a logistic model and was 
calculated by the method of Pencina et al. [27]. Different linear combinations of biomarkers 
and the PESI risk score were derived from predictions of logistic models with 6-month mortality 
as dependent and the relevant biomarkers and the PESI risk score as independent variables. 
In addition, we performed sensitivity analyses for all patients in whom a biomarker 
measurement was available irrespective of timing of blood draw as well as for patients without 
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cancer. P-values <0.05 were considered statistically significant. All analyses were performed 
using Stata 14 (Stata Corporation, College Station, Texas, U.S.A.). Reporting of the study 
conforms to STROBE statement along with references to STROBE statement and the broader 
EQUATOR guidelines [28, 29]. 
 
Results 
Prospective SWITCO65+ PE cohort – clinical and laboratory characteristics  
Of 695 patients with PE enrolled in SWITCO65+, 214 patients were included in the current 
analysis (Figure 1). Median age in this cohort was 75.0 years (IQR 69.0; 82.0) and one third of 
patients had had a prior VTE (n=67, 31%) or a provoked PE (n=64, 30%) and 15% (n=32) of 
patients had active cancer. Clinical characteristics of analysed patients, including their 
biomarker levels, are shown in Table 1 – comprising an intermediate risk cohort of patients 
(median PESI risk score of 94.0).  Distribution of biomarker levels across PESI risk score 
classes are shown in Supplemental Table S1.  In order to address a potential selection bias 
of the patients included vs. excluded patients, we performed a comparison of baseline 
characteristics between included and excluded patients (Supplemental Table S2). These two 
patient groups were very similar regarding baseline characteristics except for differences in 
blood counts attributable to exclusion of patients with infection or sepsis. Nonetheless, 6-
month mortality was higher in in- vs. excluded patients, possibly attributable to a higher burden 
of inflammation (hs-CRP) and higher ventricular strain (NT-proBNP). 
 
Discrimination of risk by hs-cTnT, NT-proBNP and hs-CRP for all-cause mortality 
During the first 6 months of follow-up, 29 patients (13.6%) died due to various reasons; 10 of 
whom died due to PE, 8 died from cancer (Supplemental Table S3). Patients in the highest 
quartile had a significantly higher risk to die during the first 6 months for hs-cTnT (adjusted HR 
10.22; 95% CI 1.79-58.34; p=0.009) with a trend for NT-proBNP (adjusted HR 4.3; 95% CI 
0.9-20.41; p=0.067) compared with the lowest quartile. Conversely no significant difference 
was found for hs-CRP when comparing the highest quartile with the lowest quartile (adjusted 
This article is protected by copyright. All rights reserved. 
HR 1.97; 95% CI 0.48-8.05; p=0.344) (Supplemental Table 4). Associations of individual 
biomarkers with all-cause mortality during 6-month follow-up are shown in Table 2.  
 
Prognostic accuracy of hs-CRP, hs-cTnT and NT-proBNP for all-cause mortality, alone 
and combined with PESI risk score 
Among the three biomarkers and the PESI risk score, the prognostic accuracy of hs-CRP (c-
statistic 0.54, CI 0.44-0.64) to predict mortality at 6 months was poor (Table 2, Figure 2). In 
contrast, hs-cTnT (c-statistic 0.72, CI 0.62-0.81), NT-proBNP (c-statistic 0.72, CI 0.63-0.80) 
and the PESI risk score (c-statistic 0.77, CI 0.69-0.84) showed good discrimination for 6-month 
mortality. 
Combining all three biomarkers with the reference model (PESI risk score) provided 
incremental discrimination of risk for all-cause mortality as assessed by IDI but not by NRI 
(Table 3).  
We additionally evaluated the predictive ability for 30-day mortality. Results are similar 
as for 6-month mortality (Supplemental Tables S5-S6 and Figure S1).  
To address whether results were similar for patients in whom a biomarker 
measurement was available irrespective of timing of blood draw (n=551), a sensitivity analysis 
was performed. The PESI risk score remained the best discriminator of risk and was only 
marginally improved by the addition of the three biomarkers (c-statistic 0.77 to 0.80) 
(Supplemental Tables S7-S9). 
A subgroup analysis excluding cancer patients showed similar results with good 
prognostic accuracy for 6-month mortality for the PESI risk score with a slightly higher 
increment in discrimination of risk when adding hs-cTnT, NT-proBNP and hs-CRP (c-statistic 
0.75 to 0.81) (Supplemental Tables S10-S12). 
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Discussion 
Our study in elderly patients with acute, haemodynamically stable PE demonstrates the 
strength of the PESI risk score for 6-months mortality. When adding the three cardiac 
biomarkers hs-cTnT, NT-proBNP and inflammatory hs-CRP to the PESI risk score, no relevant 
clinical benefit in risk stratification is achieved for this endpoint. 
Current guidelines recommend to measure biomarkers in PE patients at intermediate 
risk [8]. Our data corroborate prior data on the prognostic accuracy of hs-cTnT and NT-
proBNP for all-cause short-term mortality in patients with PE [8, 9]. However, from a clinical 
perspective our data argue in favour of using the clinical PESI risk score alone as none of the 
combinations of biomarkers (single or combined) with the PESI risk score provided 
incremental information. 
In turn, the prognostic accuracy of hs-CRP in our study for all-cause mortality during 6-
months follow-up was poor. Previous studies showed elevated levels of hs-CRP in patients 
with spontaneous VTE compared with controls [22, 23]. This association was independent of 
hereditary and laboratory risk factors for VTE, but lost its significance after adjustment for BMI 
[22, 23]. On the other hand, hs-CRP, fibrinogen, and factor VIII, were at higher levels in 
patients with idiopathic compared with secondary VTE controls [22, 23]. Of note, none of these 
studies validated the role of hs-CRP for outcome in patients with PE. Our data show that hs-
CRP at the time of diagnosis does not improve risk stratification of elderly PE patients for 6-
month mortality. Our study did not address whether hs-CRP obtained at a later time-point (>1 
day after diagnosis of PE) is associated with adverse clinical events.  
Arterial and venous thrombosis share an inflammatory pathogenesis [30]. In line with 
this concept, in a primary prevention setting, statin medication was found to prevent VTE in 
apparently healthy individuals with elevated levels of hs-CRP [31].  
Hence, in contrast to atherosclerotic cardiovascular disease, the findings of the present study 
in patients with hemodynamically stable PE suggest that the progression of disease (as 
reflected by PE-related death during 6-month follow-up) may not be attributable to an 
inflammatory process. Further, we observed a diversity of causes of death in PE patients with 
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a relatively low percentage of unequivocally PE-related deaths. This observation can also be 
viewed in opposition to atherosclerotic cardiovascular disease, where most fatalities are 
clearly related to the disease itself.  
In this elderly patient cohort, cancer accounted for a substantial proportion of short-
term mortality (27.6%) which may act as a confounding factor for elevated hsCRP at the 
diagnosis of PE. Indeed, prior data demonstrated an association of hs-CRP with cancer-
related mortality in cancer patients with VTE [32]. However, when we excluded patients with 
cancer in a subgroup analysis, we found a similarly low prognostic accuracy of hs-CRP to 
predict all-cause mortality as in the full cohort.  
 
Limitations 
Despite the prospective design with a large number of patients with PE enrolled receiving 
standardised medications and care and adjudication of adverse events by an independent 
committee, it was not feasible to confirm PE as cause of death by autopsy, although an 
association appeared clinically plausible. Yet, we do not think that this is a relevant limitation 
as most of the studies – particularly in elderly patients – are not able to provide this information. 
To account for patients with a high probability of PE as cause of death these cases were 
classified as “possibly PE-related”. 
Furthermore, this analysis comprises a subgroup of the SWITCO65+ cohort, since 
biomarker data sets were not available in the entire study population. Moreover, a disparity of 
more than 1 day between the time of blood draw and ascertainment of data for the PESI risk 
score was considered inappropriate. Interestingly, the comparison between included and 
excluded patients in a sensitivity analysis showed that the prognostic accuracy of the PESI risk 
score and the biomarkers in the two groups were not markedly different. Larger studies are 
warranted to confirm our findings. 
Given the inclusion criteria of our SWITCO-65+ cohort, this sample may not reflect the 
full prognostic spectrum of patients with PE because only elderly patients with age above 65 
years were enrolled. Nonetheless, in our study 30% of patients had a provoked index PE, 
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demonstrating a low prevalence of provoked PE compared with previous studies in younger 
patients [30, 31]. 
 
Conclusions 
The PESI risk score provides a robust discrimination of risk for death during 6 months in 
elderly patients with acute haemodynamically stable PE. Combining the PESI risk score with 
cardiac biomarkers hs-TnT, NT-proBNP and inflammatory hs-CRP did not yield a clinically 
relevant improvement in prognostic accuracy. Our findings indicate that hs-CRP is by far the 
weakest biomarker among the three analysed. 
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Legends to figures 
Figure 1: Study Flow.  
Patient enrolment and follow-up throughout the study is shown in the flow diagram. 
Figure 2. Prognostic accuracy for 6-month all-cause mortality for biomarkers and PESI 
risk score.  
Receiver operating characteristic (ROC) curve depicting the sensitivity and specificity of the 
pulmonary embolism severity index (PESI) risk score, high-sensitivity C-reactive protein (hs-
CRP), high-sensitivity cardiac troponin T (hs-cTnT) and the precursor of brain natriuretic 
peptide (NT-proBNP) in the prediction of all-cause mortality during 6-month follow-up in 
patients with pulmonary embolism.  
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Legends to tables 
Table 1. Clinical and laboratory characteristics. 
Demographic data, comorbidities, medication and laboratory data of 214 patients with 
pulmonary embolism (PE) are shown. Data are shown as absolute counts (percentages) or as 
median (interquartile ranges). Provoked index PE: major surgery, immobilisation or oestrogen 
therapy during the last 3 months before index PE. VTE, venous thromboembolism; PE, 
pulmonary embolism; DVT, deep vein thrombosis; BMI, body mass index; AC, anticoagulation; 
VKA, vitamin K antagonist. Missing data exist for: BMI, n=1; Smoking status, n=2; history of 
major bleeding, n=1; anaemia, n=1; respiratory rate, n=38; current oestrogen therapy, n=1; D-
dimer, n=13; arterial SO2, n=15; haemoglobin, n=1; leukocytes, n=1; platelets, n=2. 
Table 2. Associations of biomarkers and the PESI risk score with 6-month mortality.  
Adjusted hazard ratios (HR) are adjusted for all other biomarkers and the PESI classes 
(ordinal), indicating an independent association with 6-month mortality. Adjusted hazard ratios 
are derived as stated in Methods. 
Table 3. Prognostic accuracy of combinations of biomarkers with PESI risk score for 6-
month mortality. Prognostic accuracy is shown by AUC, integrated discrimination 
improvement, and net reclassification improvement for hs-CRP and the other biomarkers 
added to the PESI risk score. The p-value compares the AUC of the combination against the 
AUC of the PESI alone. IDI: Integrated discrimination improvement for hs-CRP and the other 
biomarkers added to the PESI score. NRI: Net reclassification improvement for hs-CRP and 
the other biomarkers added to the PESI score using a probability cutoff of 15% (i.e. high risk is 
defined as probability of mortality >15% after 6 months which roughly corresponds to the 
observed mortality). The PESI score was used continuous. 
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Table 1. Clinical and laboratory characteristics of patients with PE 
  n (%) or median (IQ-range) 
Total N N = 214 
Patient age 75.0   (69.0;   82.0) 
Gender (female) 90 (42%) 
Prior VTE 67 (31%) 
Provoked PE 64 (30%) 
Active cancer 32 (15%) 
Concomitant DVT 43 (20%) 
BMI 27.0   (24.3;   29.9) 
Smoking status  
   current smoker 16  (8%) 
   past smoker 91 (43%) 
   never smoker 105 (50%) 
Diabetes mellitus 30 (14%) 
Coronary artery disease 38 (18%) 
Chronic or acute heart failure 21 (10%) 
Chronic lung disease 30 (14%) 
Chronic renal disease 36 (17%) 
Chronic liver disease 5  (2%) 
History of major bleeding 17 (8%) 
Anaemia 67 (31%) 
Arterial hypertension 138 (64%) 
Systolic blood pressure (mmHg) 132.5  (120.0;  150.0) 
Pulse rate (per minute) 82.0   (70.8;   96.3) 
Respiratory rate (per minute) 19.0   (16.0;   22.0) 
Body temperature (°C) 36.6 (36.2; 37.0) 
Altered mental status 6 (3%) 
Current oestrogen therapy during the last 3 
months 
4  (2%) 
Lipid-lowering drugs  63 (29%) 
Statins 59 (28%) 
Concomitant antiplatelet therapy 67 (31%) 
Initial VKA therapy 196 (92%) 
Initial parenteral anticoagulation (AC) 207 (97%) 
Duration of initial AC (months) 10.0    (4.5;   25.0) 
hs-CRP [mg/L] 35.5   (14.2;   84.0) 
hs-cTnT [ng/L] 16.4    (8.0;   33.9) 
hs-cTnT > 14 ng/L 121 (57%) 
NT-proBNP [pg/mL] 646.9  (216.6; 2371.3) 
NT-proBNP > 600 pg/mL 111 (52%) 
D-dimer [ng/mL] 2792.0 (1556.5; 3972.0) 
Arterial SO2 96.0   (92.0;   97.0) 
Haemoglobin [g/dL] 13.3   (11.9;   14.4) 
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Leukocytes [G/L] 8.2    (6.7;   11.2) 
Platelets [G/L] 203.0  (157.3;  247.8) 
PESI 94.0 (80.0; 109.3) 
PESI risk class  
low risk (≤85) 75 (35%) 
intermediate risk (86-105) 69 (32%) 
high risk (106-125) 54 (25%) 
very high risk (>125) 16 (7%) 
 
AC, anticoagulation; DVT, deep vein thrombosis; VTE, venous thromboembolism; PE, 
pulmonary embolism; BMI, body mass index; VKA, vitamin K antagonist; PESI, Pulmonary 
embolism severity index; hs-CRP, High-sensitivity C-reactive protein; hs-cTnT, High-sensitivity 
cardiac Troponin T; NT-proBNP, NT-pro B-type natriuretic peptide. Provoked index PE: major 
surgery, immobilization, or estrogen therapy during the last 3 months before index PE. There 
was only one patient with very low PESI score (≤65), therefore, very low and low risk was 
combined.  
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Table 2. Associations of biomarkers and the PESI risk score with 6-month mortality 
 
 
 Crude HR (95% CI) p-value Adjusted HR* (95%-CI) p-value C-statistics (95% CI) 
PESI (ordinal,  
per risk class)# 
2.28 (1.64 to 3.19) <0.001 1.90 (1.29 to 2.79) 0.001 0.77 (0.69 to 0.84) 
hs-CRP  
(per log-unit) 
1.15 (0.91 to 1.47) 0.239 1.05 (0.80 to 1.39) 0.714 0.54 (0.44 to 0.64) 
hs-cTnT  
(per log-unit) 
1.39 (1.18 to 1.65) <0.001 1.33 (1.10 to 1.60) 0.003 0.72 (0.62 to 0.81) 
NT-proBNP  
(per log-unit) 
1.68 (1.33 to 2.12) <0.001 1.31 (1.04 to 1.66) 0.021 0.72 (0.63 to 0.80) 
 
*Adjusted for all other markers and the PESI risk classes (ordinal), i.e. the association is independent of other markers/PESI. 
#Models fit best if PESI classes are used ordinal rather than categorical or as continuous score (based on Akaike information criterion (AIC)).  
For the rank-based C-statistics, the continuous PESI score was used. 
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Table 3. Prognostic accuracy of combinations of biomarkers with PESI risk score for 6-month mortality 
 
 AUC (95% CI) p-value* IDI (95%-CI) p-value NRI (95%-CI) p-value 
PESI 0.79 (0.70 to 0.87) - Reference - Reference - 
PESI + hs-CRP 0.79 (0.70 to 0.87) 0.582 0.001 (-0.003 to 0.004) 0.596 -0.024 (-0.098 to 0.050) 0.530 
PESI + hs-cTnT 0.81 (0.74 to 0.89) 0.269 0.043 (-0.004 to 0.090) 0.074 0.114 (-0.046 to 0.275) 0.163 
PESI + NT-proBNP 0.80 (0.73 to 0.88) 0.554 0.041 (-0.001 to 0.084) 0.055 0.130 (-0.057 to 0.318) 0.173 
PESI + all 3 
biomarkers 
0.82 (0.74 to 0.90) 0.391 0.067 (0.012 to 0.123) 0.018 0.101 (-0.099 to 0.302) 0.321 
 
 
 
* The p-value compares the AUC of the combination against the AUC of the PESI risk score alone.  
PESI, Pulmonary embolism severity index; hs-CRP, High-sensitivity C-reactive protein; hs-cTnT, High-sensitivity cardiac Troponin T;  
NT-proBNP, NT-pro B-type natriuretic peptide; AUC, area under the ROC curve.  
IDI, Integrated discrimination improvement for hs-CRP and the other biomarkers added to the PESI risk score.  
NRI, Net reclassification improvement for hs-CRP and the other biomarkers added to the PESI score using a probability cutoff of 15% (i.e. high 
risk is defined as probability of mortality >15% after 6 months which roughly corresponds to the observed mortality).  
The PESI risk score was used continuous.  
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FIGURES 
Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Patients with PE and written consent 
for SWITCO65+ (n=695) 
Enrolment 
Included (n=214) 
Excluded from analysis (n=481) 
- patients denying use of data (n=7) 
- early withdrawal (first day) (n=1) 
- no initial anti-coagulation (n=4) 
- severe infection or sepsis (n=54) 
- no biosample taken (n=52) 
- no biosample result (n=26) 
- biosample drawn late (n=337) 
 
Follow-up performed (n=214) 
 - Alive (n=185) 
 - Died ≤ 6 months follow-up (n=29) 
 
Lost to follow-up (n=7) 
 - Refused follow-up (n=7) 
Follow-up 6 months 
Analyzed (n=214) 
Analysis 
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Figure 2 
 
 
  
0
.0
0
0
.2
5
0
.5
0
0
.7
5
1
.0
0
S
e
n
s
it
iv
it
y
 
0.00 0.25 0.50 0.75 1.00
 
1-Specificity
hs-CRP
PESI
hs-cTnT
NT-proBNP
